Pneumothorax Treatment Market size is poised to reach USD 60 Billion by the end of 2036, growing at a CAGR of 7% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of pneumothorax treatment was USD 22 Billion. The growth of the market is due to the burgeoning occurrence of pneumothorax inside the worldwide population, due to the high prevalence of lung diseases which includes asthma, COPD, cystic fibrosis, tuberculosis, and many more. For instance, studies display that the prevalence of COPD was predicted to be 10% in 2020 for each male and female, or 480 million cases globally. As a result, the high incidence of pneumothorax infection because of rising lung sicknesses in the global populace necessitates a larger marketplace for related treatment, diagnostics, and preventive measures.
In addition, the rising smoking rate in the population would also support the industry and accelerate its expansion during the projection period. According to data published by the World Health Organization, an estimated 36.7% of males and 7.8% of women worldwide smoked tobacco in 2020, making up 22.3% of the global population.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~7% |
|
Base Year Market Size (2023) |
~ USD 22 Billion |
|
Forecast Year Market Size (2036) |
~ USD 60 Billion |
|
Regional Scope |
|
End-user (Hospital, Clinics, Ambulatory Distribution Channel)
The hospital segment in pneumothorax treatment market is estimated to gain a significant share of about ~44% in the year 2036. The availability of hospitals throughout the world and the availability of rapid and simple treatments for pneumothorax infections are both factors contributing to the segment's growth, which is anticipated to fuel market expansion. For reference, the number of hospitals worldwide as of 2021 is estimated to be 165,000. Hospitals are the primary end users in the pneumothorax treatment market, offering therapy, post-treatment care, and assistance for diagnostics to patients infected with pneumothorax.
Type (Primary Spontaneous, Secondary Spontaneous, Latrogenic, Injury Related, Catamenial)
The secondary spontaneous pneumothorax segment in pneumothorax treatment market is estimated to gain the largest revenue share of about ~30% in the year 2036. The segment growth can be attributed to the growing prevalence of persistent lung diseases consisting of bronchial asthma, interstitial lung disease (ILD), cystic fibrosis, or lung cancers. A secondary spontaneous pneumothorax refers to a spontaneous pneumothorax in a patient with preexisting persistent lung ailments. Studies show that around 545 million people worldwide, or 7·4% of the total population, suffer from a chronic respiratory ailment. Furthermore, because of the growing older populations, there can be a rise in the incidence of secondary spontaneous pneumothorax (SSP) because it typically happens in older populations, mostly with accompanying health conditions. Thus, the market segment is expected to hold the largest market share in the forecast period.
|
Type |
|
|
Treatment |
|
|
Diagnosis |
|
|
End-User |
|
North America Market Forecast
The pneumothorax treatment market in North America, is anticipated to hold the largest with a share of about ~28% by the end of 2036. The market growth in the region is also expected on account of the rising prevalence of pneumothorax due to the rise in chronic lung disease. Based on research, 2.28 million Canadians have asthma, placing the nation among those with the highest asthma prevalence globally. Furthermore, asthma and COPD are among the chronic lung diseases that affect approximately 34 million Americans. Moreover, high awareness of pneumothorax infection and easy availability of hospitals and medical centers in the region results, in more people likely to choose early diagnosis and treatment, fueling the market growth in the region. Additionally, the region's expanding healthcare sector and increasing expenditures in healthcare are also expected to propel the market's expansion in the years to come.
APAC Market Analysis
The Asia Pacific pneumothorax treatment market is estimated to be the second largest, registering a share of about ~21% by the end of 2036. The market’s expansion can be attributed majorly to the rising awareness about respiratory health and the burgeoning prevalence of lung-related diseases in the region. According to research, about 65 million individuals in India, and around 100 million individuals in China suffer from chronic obstructive pulmonary disease (COPD), which makes up nearly 25% of all COPD cases worldwide. This high incidence of lung-related diseases can be attributed to the unhealthy lifestyle, high pollution rates, and high number of smoking population in the region. In addition, the presence of major market players in developing countries like China India Japan, & the Philippines and government programs aimed at enhancing healthcare access across the region are anticipated to fuel pneumothorax treatment market expansion over the projected period.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?